Earnings Releases·Nov 10, 2026, 4:05 PM ET

Stereotaxis — Q3 2026 Earnings Summary

Revenue reached $8.9 million, a 20% year-over-year and 16% sequential increase, driven by a 60% surge in system sales to $3.0 million, though recurring revenue grew only 6% year-over-year amid supply constraints.
The company reported a net loss of $6.5 million with negative cash flow of $6.5 million, while announcing a convertible note financing of up to $24 million that would raise pro forma cash to $16 million.
Strategic momentum includes the closing of the Robocath acquisition and a new collaboration with Canon, alongside a business model pivot toward scalable systems and disposable catheters to drive recurring revenue.
Management projects adjusted operating expenses of approximately $8 million per quarter and a pathway to cash-flow profitability within the next year, pending the resolution of supply chain issues and installation of GenesisX systems.